Is CLBS or EQR a better dividend investment in 2026?

CLBS currently yields 131.33% with a 5% 5-year dividend growth rate. EQR yields 4.73% with 5% growth. The better choice depends on your goal: CLBS offers higher current income.

What is the dividend yield difference between CLBS and EQR?

CLBS has a forward dividend yield of 131.33% ($0.56/share annually). EQR yields 4.73% ($2.77/share annually). The yield gap is 126.60 percentage points.

Home › Compare › CLBS vs EQR

CLBS vs EQR: Dividend Comparison 2026

CLBS yields 131.33% · EQR yields 4.73%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 CLBS wins by $12.95M in total portfolio value

INVESTMENT

TIME HORIZON10 years

CLBS

● Live price

131.33%

Share price

$0.43

Annual div

$0.56

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$12.99M

Annual income

$5,201,713.69

Full CLBS calculator →

EQR

● Live price

4.73%

Share price

$58.58

Annual div

$2.77

5Y div CAGR

15.8%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$40.5K

Annual income

$3,819.61

Full EQR calculator →

Portfolio growth — CLBS vs EQR

📍 CLBS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	CLBS	EQR
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, CLBS + EQR cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

CLBS pays

EQR pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CLBS

Annual income on $10K today (after 15% tax)

$11,163.23/yr

After 10yr DRIP, annual income (after tax)

$4,421,456.64/yr

EQR

Annual income on $10K today (after 15% tax)

$401.93/yr

After 10yr DRIP, annual income (after tax)

$3,246.67/yr

At 15% tax rate, CLBS beats the other by $4,418,209.97/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CLBS + EQR for your $10,000?

CLBS: 50%EQR: 50%

100% EQR50/50100% CLBS

Portfolio after 10yr

$6.52M

Annual income

$2,602,766.64/yr

Blended yield

39.94%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

CLBS

No analyst data

Altman Z

-42.9

Piotroski

2/9

EQR

Analyst Ratings

Buy

Hold

Sell

Consensus: Hold

Price Target

$70.35

+20.1% upside vs current

Range: $63.00 — $78.50

Altman Z

1.8

Piotroski

7/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CLBS buys

EQR buys

No recent congressional trades found for CLBS or EQR in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricCLBSEQR

Forward yield	131.33% ✓	4.73%
Annual dividend / share	$0.56	$2.77 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	15.8% ✓
Portfolio after 10y	$12.99M	$40.5K ✓
Annual income after 10y	$5,201,713.69 ✓	$3,819.61
Total dividends collected	$11.90M	$16.9K ✓
Payment frequency	quarterly	quarterly
Sector	Stock	REIT

Year-by-year: CLBS vs EQR ($10,000, DRIP)

Year	CLBS Portfolio	CLBS Income/yr	EQR Portfolio	EQR Income/yr	Gap
1← crossover	$23,833	$13,133.21	$11,248	$547.57	+$12.6K → CLBS
2	$54,754	$29,252.94	$12,701	$666.53	+$42.1K → CLBS
3	$121,396	$62,809.15	$14,405	$814.59	+$107.0K → CLBS
4	$260,039	$130,144.39	$16,413	$999.84	+$243.6K → CLBS
5	$538,781	$260,539.45	$18,795	$1,232.92	+$520.0K → CLBS
6	$1,080,999	$504,503.28	$21,639	$1,527.95	+$1.06M → CLBS
7	$2,102,673	$946,004.75	$25,057	$1,903.80	+$2.08M → CLBS
8	$3,969,574	$1,719,713.85	$29,197	$2,385.87	+$3.94M → CLBS
9	$7,281,647	$3,034,202.37	$34,250	$3,008.70	+$7.25M → CLBS
10	$12,993,076	$5,201,713.69	$40,467	$3,819.61	+$12.95M → CLBS

CLBS vs EQR: Complete Analysis 2026

CLBS — Stock

Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Full CLBS Calculator →

EQR — REIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →

📬

Get this CLBS vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CLBS vs SCHD CLBS vs JEPI CLBS vs O CLBS vs KO CLBS vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.